Literature DB >> 21555961

Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay.

Rachel Ware Miller1, Alan Smith, Christopher P DeSimone, Leigh Seamon, Scott Goodrich, Iwona Podzielinski, Lori Sokoll, John R van Nagell, Zhen Zhang, Frederick R Ueland.   

Abstract

OBJECTIVE: The American College of Obstetricians and Gynecologists (the College) published referral guidelines for women with a pelvic mass that incorporate CA 125. A new multivariate index assay assesses the malignant risk of ovarian tumors before surgery. Our objective was to estimate the performance of the College guidelines with this new multivariate index assay.
METHODS: This prospective, multi-institutional trial included 27 primary care and specialty sites throughout the United States. The College guidelines were evaluated in women scheduled for surgery for an ovarian mass. Clinical criteria and blood for biomarkers were collected before surgery. A standard CA 125-II assay was used and the value applied to the multivariate index assay algorithm and the CA 125 analysis. Study results were correlated with surgical pathology.
RESULTS: Of the 590 women enrolled with ovarian mass on pelvic imaging, 516 were evaluable. There were 161 malignancies (45 premenopausal and 116 postmenopausal). The College referral criteria had a modest sensitivity in detecting malignancy. Replacing CA 125 with the multivariate index assay increased the sensitivity (77-94%) and negative predictive value (87-93%) while decreasing specificity (68-35%) and positive predictive value (52-40%). Similar trends were noted for premenopausal women and early-stage disease.
CONCLUSION: Replacing CA 125 with the multivariate index assay improves the sensitivity and negative predictive value of the College referral guidelines while decreasing specificity and positive predictive value. The high sensitivity is maintained in premenopausal women and early-stage disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21555961     DOI: 10.1097/AOG.0b013e31821b1d80

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  29 in total

1.  An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers.

Authors:  Zhen Zhang
Journal:  Rev Obstet Gynecol       Date:  2012

Review 2.  The role of biomarkers in the management of epithelial ovarian cancer.

Authors:  Wei-Lei Yang; Zhen Lu; Robert C Bast
Journal:  Expert Rev Mol Diagn       Date:  2017-05-15       Impact factor: 5.225

Review 3.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

4.  MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer.

Authors:  Ying-Chun Gao; Jie Wu
Journal:  Tumour Biol       Date:  2015-02-01

Review 5.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

6.  Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Expert Opin Med Diagn       Date:  2012-03

7.  In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans.

Authors:  Angelito I Nepomuceno; Huanjie Shao; Kai Jing; Yibao Ma; James N Petitte; Michael O Idowu; David C Muddiman; Xianjun Fang; Adam M Hawkridge
Journal:  Anal Bioanal Chem       Date:  2015-07-10       Impact factor: 4.142

Review 8.  Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

9.  Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.

Authors:  Edward E Partridge; Robert T Greenlee; Thomas L Riley; John Commins; Lawrence Ragard; Jian-Lun Xu; Saundra S Buys; Philip C Prorok; Mona N Fouad
Journal:  Obstet Gynecol       Date:  2013-01       Impact factor: 7.661

10.  Hepatic proteomic analysis revealed altered metabolic pathways in insulin resistant Akt1(+/-)/Akt2(-/-) mice.

Authors:  Brian A Pedersen; Weiwen Wang; Jared F Taylor; Omar S Khattab; Yu-Han Chen; Robert A Edwards; Puya G Yazdi; Ping H Wang
Journal:  Metabolism       Date:  2015-09-12       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.